SCHEMBL5513632

SCHEMBL5513632

Oc1noc2ccc(Cl)cc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.49
ALDH1A1 P00352 6/20 0.44
KMT2A Q03164 4/20 0.44
MEN1 O00255 2/20 0.44
MAPT P10636 1/20 0.44
GFER P55789 1/20 0.44
ESR1 P03372 3/20 0.42
ESR2 Q92731 3/20 0.42
AHR P35869 1/20 0.41
HTR3A P46098 2/20 0.40
TSHR P16473 2/20 0.40
HSD17B10 Q99714 2/20 0.40
CYP3A4 P08684 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
NQO1 P15559 1/20 0.40
EPHX2 P34913 1/20 0.40
LMNA P02545 1/20 0.40
GPR55 Q9Y2T6 1/20 0.40
HSP90AA1 P07900 1/20 0.39
CASP1 P29466 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29793168 1.00 FAAH (0.49) FAAHALDH1A1KMT2AMEN1MAPT
SCHEMBL1836503 0.84 ALDH1A1 (0.49) FAAHALDH1A1KMT2AMEN1MAPT
SCHEMBL5508112 0.79 ESR1 (0.63) ALDH1A1MAPTESR1ESR2HSD17B10
SCHEMBL6989194 0.79 FAAH (0.51) FAAHALDH1A1KMT2AMEN1MAPT
SCHEMBL12879280 0.76 ESR1 (0.42) MAPTESR1ESR2HSP90AA1
SCHEMBL1759343 0.76 MAPT (0.54) KMT2AMEN1MAPTESR1ESR2
SCHEMBL5511112 0.76 ESR1 (0.42) MAPTESR1ESR2HTR3ATDP1
SCHEMBL12646518 0.76 FAAH (0.49) FAAHALDH1A1KMT2AMEN1MAPT
SCHEMBL2708342 0.76 PIM1 (0.49) ALDH1A1ESR1ESR2TSHRLMNA
SCHEMBL5511923 0.76 ESR1 (0.42) MAPTESR1ESR2HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240301003-A1 PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX NONO INC. (CA) 2024-09-12 US claimed
EP-4274596-A1 PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX NoNO Inc. (CA) 2023-11-15 EP claimed
WO-2022150655-A1 PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX NONO INC. (CA) 2022-07-14 WO claimed
US-20160206583-A1 AMINO ACID TREATMENT OF SEIZURES THE JOHNS HOPKINS UNIVERSITY (US) 2016-07-21 US claimed
WO-2015031493-A1 AMINO ACID TREATMENT OF SEIZURES THE JOHNS HOPKINS UNIVERSITY (US) 2015-03-05 WO claimed
CN-102614514-B GLP-1 acceptor agonists used for treating pains WANG YONGXIANG 2014-12-10 CN claimed
US-20240301003-A1 PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX NONO INC. (CA) 2024-09-12 US disclosed
EP-4274596-A1 PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX NoNO Inc. (CA) 2023-11-15 EP disclosed
CN-116897051-A Plasmin peptides for increasing therapeutic index 诺诺公司 2023-10-17 CN disclosed
WO-2022150655-A1 PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX NONO INC. (CA) 2022-07-14 WO disclosed
US-20160206583-A1 AMINO ACID TREATMENT OF SEIZURES THE JOHNS HOPKINS UNIVERSITY (US) 2016-07-21 US disclosed
WO-2015031493-A1 AMINO ACID TREATMENT OF SEIZURES THE JOHNS HOPKINS UNIVERSITY (US) 2015-03-05 WO disclosed
US-8778688-B2 High-throughput methods for determining pharmacological levels of plasma D-serine THE JOHNS HOPKINS UNIVERSITY (US) 2014-07-15 US disclosed
CN-1098843-C Isoxazoles SANKYO CO (JP) 2003-01-15 CN disclosed
US-6096771-A ISOXAZOLE DERIVATIVES EXHIBITING EXCELLENT TYPE B AND TYPE A MONOAMINE OXIDASE INHIBITORY ACTIVITIES, THEREFORE USEFUL FOR PREVENTING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE SANKYO COMPANY, LIMITED (JP) 2000-08-01 US disclosed
US-5965591-A MONOAMINE OXIDASE INHIBITOR; FOR PROPHYLAXIS AND TREATING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE SANKYO COMPANY, LIMITED (JP) 1999-10-12 US disclosed
CN-1162957-A Isoxazole derivatives SANKYO CO (JP) 1997-10-22 CN disclosed
EP-0779281-A1 ISOXAZOLES SANKYO COMPANY LIMITED (JP) 1997-06-18 EP disclosed
US-5578627-A FOR TREATING CEREBRAL CIRCULATORY DISORDER, HEAD INJURY SEQUELAE AND/OR EPILEPSY TOYAMA CHEMICAL CO., LTD. (JP) 1996-11-26 US disclosed
EP-0665226-A1 NOVEL 1,2-BENZISOXAZOLE DERIVATIVE OR SALT THEREOF, AND BRAIN PROTECTIVE AGENT COMPRISING THE SAME TOYAMA CHEMICAL CO., LTD. (JP) 1995-08-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240301003-A1 PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX DAO, DNPEP, DDO FAAH 3581/4885ALDH1A1 3618/4885KMT2A 3887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.